Skip to main content
SpringerLink
Log in

Treatment choices in impetigo

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Failla DM, Pankey GA. Optimum outpatient therapy of skin and skin structure infections. Drugs 1994; 48: 172–8

    Article  PubMed  CAS  Google Scholar 

  2. Demidovich CW, Wittler RR, Ruff ME, et al. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990; 144: 1313–5

    PubMed  CAS  Google Scholar 

  3. Rice TD, Duggan AK, DeAngelis C. Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Pediatrics 1992; 89: 210–4

    PubMed  CAS  Google Scholar 

  4. Dagan R, Yair B-D. Comparison of amoxicillin and clavulanic acid (Augmentin) for the treatment of nonbullous impetigo. Am J Dis Child 1989; 143: 916–8

    PubMed  CAS  Google Scholar 

  5. Feder HM, Acrahamian LM, Grant-Kels JM. Is penicillin still the drug of choice for non-bullous impetigo? Lancet 1991; 338: 803–5

    Article  PubMed  Google Scholar 

  6. British National Formulary No. 28. London: The Pharmaceutical Press, 1994; 214

  7. Leyden JJ. Review of mupirocin ointment in the treatment of impetigo. Clin Pediatr 1992; 31: 549–53

    Article  CAS  Google Scholar 

  8. Dagan R, Yair B-D. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992; 36: 287–90

    Article  PubMed  CAS  Google Scholar 

  9. Sutton JB. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in facial impetigo. Curr Thes Res 1992; 51: 673–8

    Google Scholar 

  10. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992; 31: 1–9

    Article  PubMed  CAS  Google Scholar 

  11. Langdon CG, Mahapatra KS. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in actue skin sepsis. Curr Thes Res 1990; 48: 174–80

    Google Scholar 

  12. Martindale. The Extra Pharmacopoeia, 30th ed. London: The Pharmaceutical Press, 1993; 183

    Google Scholar 

  13. Gooch WM, Kaminester L, Cole GW, et al. Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures. Dermatologica 1991; 183: 36–43

    Article  PubMed  Google Scholar 

  14. Britton Lt JW, Fajardo Capt JE, Krafte-Jacobs LCDR B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990; 117: 827–9

    Article  Google Scholar 

  15. McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol 1990; 22: 883–5

    Article  PubMed  CAS  Google Scholar 

  16. Parish LC, Witkowski JA. Systemic management of cutaneous bacterial infections. Am J Med 1991; 91 Suppl 6A: 106–10

    Article  Google Scholar 

  17. Takahashi H and the Japanese Collaborative Study Group of Sparfloxacin in Dermatology. Sparfloxacin in the treatment of skin and soft tissue infections. Drugs 1993; 45 Suppl 3: 386

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Treatment choices in impetigo. Drugs Ther. Perspect 5, 7–9 (1995). https://doi.org/10.2165/00042310-199505090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505090-00003

Search

Navigation